The therapeutic puzzle of aplastic anemia just became more complex, with new evidence that a leading drug treatment affects different blood cell populations in dramatically different ways. This variability could explain why some patients respond better than others to current therapies and points toward more personalized treatment approaches. Using advanced stem cell modeling techniques, investigators examined how eltrombopag—a drug that stimulates blood cell production—interacts with various types of blood-forming cells found in aplastic anemia patients. They focused particularly on immune-escape clones, specialized cell populations that emerge when the immune system attacks normal blood-forming stem cells. These escape clones survive by losing specific surface markers that make them targets for immune destruction. The research revealed that eltrombopag produces markedly different responses across distinct cell populations. Some immune-escape clones showed enhanced proliferation under drug treatment, while others demonstrated minimal response. At the molecular level, cells varied significantly in their expression of CD110, the receptor that eltrombopag targets, along with downstream signaling proteins including phosphorylated STAT5, FOXM1, and E2F1. This finding challenges the assumption that eltrombopag works uniformly across all blood cell types in aplastic anemia. The clonal diversity observed suggests that treatment outcomes may depend heavily on which specific cell populations dominate in individual patients. From a clinical perspective, this research could inform more precise dosing strategies and help predict which patients are most likely to benefit from eltrombopag therapy. However, the study was conducted using laboratory models rather than patient samples, limiting immediate clinical applications. The work represents an important step toward understanding the cellular complexity underlying treatment responses in this challenging blood disorder.